Right here’s Why Novo Nordisk (NVO) Traded Down in Q3

Chautauqua Capital Administration, a division of Baird Asset Administration, is a boutique funding agency that launched its third-quarter 2025 investor letter for the “Baird Chautauqua Worldwide and World Progress Fund”. A duplicate of the letter may be downloaded right here. World fairness markets delivered strong leads to the third quarter, pushed by the decision of serious commerce conflicts and a shift in U.S. financial coverage towards a extra dovish stance. Baird Chautauqua Worldwide Progress Fund underperformed the benchmark, MSCI ACWI ex-U.S. Index – ND, within the quarter, pushed by inventory choice within the info know-how, financials, and industrials sectors, which detracted probably the most from returns. The Baird Chautauqua World Progress Fund additionally trailed the benchmark, MSCI ACWI Index – ND, within the quarter as inventory choice within the info know-how, financials, and industrials sectors detracted probably the most from returns. As well as, please examine the fund’s prime 5 holdings to know its greatest picks in 2025.

In its third-quarter 2025 investor letter, Baird Chautauqua Worldwide and World Progress Fund highlighted shares akin to Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages within the analysis and improvement, manufacture, and distribution of pharmaceutical merchandise. The one-month return of Novo Nordisk A/S (NYSE:NVO) was 7.99%, and its shares misplaced 40.46% of their worth over the past 52 weeks. On December 30, 2025, Novo Nordisk A/S (NYSE:NVO) inventory closed at $51.22 per share, with a market capitalization of $227.595 billion.

Baird Chautauqua Worldwide and World Progress Fund said the next relating to Novo Nordisk A/S (NYSE:NVO) in its third quarter 2025 investor letter:

“Novo Nordisk A/S (NYSE:NVO) reported lower-than-expected revenues and earnings in a pre-earnings press launch, minimize steerage, and introduced a CEO change one week earlier than its quarterly earnings name. The important thing components cited are compound provide overhang and a difficult Ozempic prescription pattern. The same mixture of CEO change and steerage minimize occurred in 2016. We imagine Novo’s merchandise and pipeline supply higher worth than what’s accounted for in its present valuation.”

Novo Nordisk A/S (NYSE:NVO) just isn’t on our listing of 30 Most Common Shares Amongst Hedge Funds. As per our database, 50 hedge fund portfolios held Novo Nordisk A/S (NYSE:NVO) on the finish of the third quarter, which was 45 within the earlier quarter. Whereas we acknowledge the potential of Novo Nordisk A/S (NYSE:NVO) as an funding, we imagine sure AI shares supply higher upside potential and carry much less draw back danger. Should you’re in search of an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.